An underground market for unlicensed slimming drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.
Investigational Drug Gaining Popularity Via Social Media
The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its supposed fat-burning effects. Followers are urged to message these profiles directly for source information, while also obtaining promotional offers.
Thriving Trade on Social Networks
Separately, a robust market exists on messaging services, where communities with thousands of members share comparison photos, administration instructions and claims of next-day British shipping. Sellers market the drug there before redirecting buyers to other platforms for transactions.
Learning About The Experimental Drug
Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could help patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed digitally as the next Ozempic.
Healthcare Experts Express Worries
Nevertheless, doctors and chemists have cautions that the sale of what remains an unapproved drug in the United Kingdom is a cause for concern and could result in users administering substances of unknown origin.
Some experts stated the demand for retatrutide could be linked to the increasing cost of approved weight loss products such as Mounjaro.
Regulatory Position and Implementation
Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several influencers try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and distribution can still violate pharmaceutical, advertising, and consumer regulations, risking penalties, prosecution or prison.
Platform Response and Material Elimination
According to the social media company, the platform has taken down problematic material and prohibited associated hashtags and query recommendations. The company stated it was dedicated to maintaining the platform safe and allocating resources in strengthening enforcement strategies.
Online Marketplace Activities
Investigations also found communities with up to nine thousand members marketing retatrutide using Telegram's built-in search feature, which operates like a online catalog. Typing “retatrutide” immediately displays channels with thousands of members, populated with photos of weight loss, positive testimonials and step-by-step guides for preparing or administering at home.
After minutes of entering one community, a vendor shared contact information, where most transactions occur. The seller sent an instruction manual and promised delivery within 48 hours. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None asked about weight, health issues or past usage.
Product Information and Pricing
Inside these communities, posts display black plastic packages with Royal Mail stickers, stating to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”
Buyers can select between dry substance containers, prepared at residence with sterile water, or ready-to-use pens typically priced at 160 pounds for 20mg. When questioned how long a injector should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.
Service Moderation and Security Measures
A representative for the messaging service stated it actively moderated harmful content on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Expert Cautions
“People are administering materials they cannot confirm. Although the research behind retatrutide is sound, these online products may not contain what they advertise,” stated Jason Murphy, the head of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With prices increasing, patients are turning to social media. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she said.
Her staff has already seen individuals injured by self-injection from unverified suppliers. “We understand the frustration, but buying from Telegram or WhatsApp is gambling with your health,” stated Wyllie. “These substances could be contaminated or improperly measured.”
Producer Statement
A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can market [it] for human use,” they explained, adding that any item “misleadingly claiming itself as a Lilly investigational substance not yet approved … may expose patients to possibly serious medical dangers”.
